(89)Zirconium-labelled girentuximab ((89)Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma

INTRODUCTION: Bladder cancer is a lethal disease with a rising incidence on a background of limited conventional imaging modalities for staging (either CT of the chest-abdomen-pelvis or 18F-fluorodeoxyglucose positron emitting tomography (FDG-PET/CT)). CT is known to have relatively low sensitivity...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Zubaidi, Mohammed, Viswambaram, Pravin, McCombie, Steve, Liow, Elizabeth, Lenzo, Nat, Ferguson, Tom, Redfern, Andrew D, Gauci, Richard, Hayne, Dickon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Urology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014075/
https://www.ncbi.nlm.nih.gov/pubmed/35428649
http://dx.doi.org/10.1136/bmjopen-2021-060478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014075/
https://www.ncbi.nlm.nih.gov/pubmed/35428649
http://dx.doi.org/10.1136/bmjopen-2021-060478

Ejemplares similares